Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
July 29, 2024 7:18 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "BMY's noteworthy outperformance on Friday July 26 (+~11% vs. flat XLV), while it occurred amidst favorable shifts in the broader market macro backdrop, was earned, in our... More
Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance
July 26, 2024 7:51 AM EDTBristol-Myers Squibb (NYSE: BMY) shares rallied more than 5% premarket Friday as the company reported a robust second quarter, surpassing Wall Street's expectations for both earnings and revenue, and raised its full-year guidance.
The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.07, significantly higher than the analyst estimate of $1.64. Revenue for the quarter was also strong at $12.2 billion, beating the consensus estimate of $11.52 billion and marking a 9% increase from the same quarter last year, or an 11% rise adjusting for foreign exchange.
The company's performance was propelled by its Growth Portfolio, which saw... More

